Yuanbin Chen
About
Yuanbin Chen is a scholar working on Oncology, Molecular Biology and Epidemiology.
According to data from OpenAlex, Yuanbin Chen has authored 23 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 7 papers in Epidemiology. Recurrent topics in Yuanbin Chen's work include Lung Cancer Research Studies (20 papers), Cancer therapeutics and mechanisms (12 papers) and Neuroendocrine Tumor Research Advances (6 papers). Yuanbin Chen is often cited by papers focused on Lung Cancer Research Studies (20 papers), Cancer therapeutics and mechanisms (12 papers) and Neuroendocrine Tumor Research Advances (6 papers). Yuanbin Chen collaborates with scholars based in United States, Spain and Germany. Yuanbin Chen's co-authors include Dmytro Trukhin, Niels Reinmuth, Galina Statsenko, Jonathan W. Goldman, Luis Paz‐Ares, Artem Poltoratskiy, Haiyi Jiang, Mustafa Özgüroğlu, Олександр Войтко and Maximilian J. Hochmair and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.
In The Last Decade
Yuanbin Chen
18 papers receiving 145 citations
Peers
Yuanbin Chen
Victoria E. Wang United States
Vanesa Gutiérrez Spain
Sujay Shah United States
Leah Ensell United Kingdom
Natalie Byrne United Kingdom
Kim Norris United States
Л. Д. Жуйкова Russia
Marc Cucurull Spain
Marina Sahade Brazil
Alice Baggi Italy
Citations per year, relative to Yuanbin Chen Yuanbin Chen (= 1×)
peers
Victoria E. Wang
Countries citing papers authored by Yuanbin Chen
Since
Specialization
Citations
This map shows the geographic impact of Yuanbin Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanbin Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanbin Chen more than expected).
Fields of papers citing papers by Yuanbin Chen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yuanbin Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanbin Chen. The network helps show where Yuanbin Chen may publish in the future.
Co-authorship network of co-authors of Yuanbin Chen
This figure shows the co-authorship network connecting the top 25 collaborators of Yuanbin Chen. A scholar is included among the top collaborators of Yuanbin Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanbin Chen. Yuanbin Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Patel, Sapna P., Víctor M. Prieto, M. J. S. Lowe, et al.. (2025). 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801. Annals of Oncology. 36. S882–S883.
2.
Senan, Suresh, Ying Cheng, Byoung Chul Cho, et al.. (2025). 297MO: Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC. Journal of Thoracic Oncology. 20(3). S181–S182.
3.
Hann, Christine L., Ying Cheng, David R. Spigel, et al.. (2025). Abstract CT094: Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC. Cancer Research. 85(8_Supplement_2). CT094–CT094.
4.
Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125.
5.
Iyengar, P., David R. Spigel, Yuanbin Chen, et al.. (2024). Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs). International Journal of Radiation Oncology*Biology*Physics. 120(2). S8–S9.
6.
Wu, Lei, Wei‐Wen Su, Wan‐Jen Hong, et al.. (2024). P1.13A.07 Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study. Journal of Thoracic Oncology. 19(10). S209–S209.
7.
Spigel, David R., Ying Cheng, Byoung Chul Cho, et al.. (2024). ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).. Journal of Clinical Oncology. 42(17_suppl). LBA5–LBA5.
8.
Othus, Megan, Víctor M. Prieto, Elizabeth I. Buchbinder, et al.. (2022). LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801). Annals of Oncology. 33. S1408–S1408.
9.
Reinmuth, Niels, M.C. Garassino, Yuanbin Chen, et al.. (2022). 141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study. Annals of Oncology. 33. S97–S98.
10.
Spigel, David R., Luis Paz‐Ares, Yuanbin Chen, et al.. (2021). MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity. Journal of Thoracic Oncology. 16(1). S32–S32.
11.
Thomas, Anish, Federico Cappuzzo, Noboru Yamamoto, et al.. (2021). 1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250. Annals of Oncology. 32. S1171–S1171.
12.
Paz‐Ares, Luis, David R. Spigel, Yuanbin Chen, et al.. (2021). FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S216–S216.
13.
Paz‐Ares, Luis, Yuanbin Chen, Niels Reinmuth, et al.. (2021). LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Annals of Oncology. 32. S1338–S1338.
14.
Zheng, Yingying, Dayong Jin, Mustafa Özgüroğlu, et al.. (2021). P48.21 Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN. Journal of Thoracic Oncology. 16(3). S508–S508.
15.
Ponce, Santiago, Karl Brendel, David R. Spigel, et al.. (2020). 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC). Annals of Oncology. 31. S1038–S1039.
16.
Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1212–S1213.
17.
Goldman, Jonathan W., Marina Chiara Garassino, Yuanbin Chen, et al.. (2020). 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology. 31. S1388–S1389.
18.
Rodríguez, Luis Paz-Ares, David R. Spigel, Yuanbin Chen, et al.. (2019). OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S211–S212.
19.
Özgüroğlu, Mustafa, Jonathan W. Goldman, Niels Reinmuth, et al.. (2019). LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN. Annals of Oncology. 30. xi66–xi66.
20.
Nishio, Makoto, Jun Ho Ji, Katsuyuki Hotta, et al.. (2019). Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. Annals of Oncology. 30. ix197–ix198.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Victoria E. Wang Breakdown of academic impact, for papers by Vanesa Gutiérrez Breakdown of academic impact, for papers by Sujay Shah Breakdown of academic impact, for papers by Leah Ensell Breakdown of academic impact, for papers by Natalie Byrne Breakdown of academic impact, for papers by Kim Norris Breakdown of academic impact, for papers by Л. Д. Жуйкова Breakdown of academic impact, for papers by Marc Cucurull Breakdown of academic impact, for papers by Marina Sahade Breakdown of academic impact, for papers by Alice Baggi